Search
Cangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalAn advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset … Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
Categories: Heterocyclic Compounds, 2-RingSynonyms: [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acidAvasimibe
go.drugbank.com/drugs/DB06442ExperimentalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A InducersDotarizine
go.drugbank.com/drugs/DB06446ExperimentalCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingIP501
go.drugbank.com/drugs/DB06450ExperimentalIP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis.
Tecastemizole
go.drugbank.com/drugs/DB06457ExperimentalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingRemacemide
go.drugbank.com/drugs/DB06458ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsMitumomab
go.drugbank.com/drugs/DB06462ExperimentalMitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.
IR502
go.drugbank.com/drugs/DB06463ExperimentalIR502 (Zorcell) is a potential treatment for psoriasis.
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.